{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:55:22Z","timestamp":1774040122807,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,9,15]],"date-time":"2009-09-15T00:00:00Z","timestamp":1252972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1038\/sj.bjc.6605322","type":"journal-article","created":{"date-parts":[[2009,9,15]],"date-time":"2009-09-15T20:01:12Z","timestamp":1253044872000},"page":"1233-1240","source":"Crossref","is-referenced-by-count":55,"title":["Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer"],"prefix":"10.1038","volume":"101","author":[{"given":"O","family":"Bratt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"H\u00e4ggman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Ahlgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6","family":"Nordle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bj\u00f6rk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-E","family":"Damber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,15]]},"reference":[{"key":"BF6605322_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/PPO.0b013e318161c014","volume":"14","author":"JB Aragon-Ching","year":"2008","unstructured":"Aragon-Ching JB, Dahut WL (2008) The role of angiogenesis inhibitors in prostate cancer. Cancer J 14: 20\u201325","journal-title":"Cancer J"},{"key":"BF6605322_CR2","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","volume":"13","author":"AJ Armstrong","year":"2007","unstructured":"Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13: 6396\u20136403","journal-title":"Clin Cancer Res"},{"key":"BF6605322_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","volume":"53","author":"N Bhojani","year":"2008","unstructured":"Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53: 917\u2013930","journal-title":"Eur Urol"},{"key":"BF6605322_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/annonc\/mdi098","volume":"16","author":"P Boyle","year":"2005","unstructured":"Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481\u2013488","journal-title":"Ann Oncol"},{"key":"BF6605322_CR5","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461\u20133467","journal-title":"J Clin Oncol"},{"key":"BF6605322_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/1078-0432.CCR-07-1355","volume":"14","author":"WL Dahut","year":"2008","unstructured":"Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, AragonChing JB, Venitz J, Jones E, Chen CC, Figg WD (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14: 209\u2013214","journal-title":"Clin Cancer Res"},{"key":"BF6605322_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/pros.20573","volume":"67","author":"SL Dalrymple","year":"2007","unstructured":"Dalrymple SL, Becker RE, Isaacs JT (2007) The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 67: 790\u2013797","journal-title":"Prostate"},{"key":"BF6605322_CR8","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0140-6736(08)60729-1","volume":"371","author":"JE Damber","year":"2008","unstructured":"Damber JE, Aus G (2008) Prostate cancer. Lancet 371: 1710\u20131721","journal-title":"Lancet"},{"key":"BF6605322_CR9","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.juro.2006.07.002","volume":"176","author":"TJ Daskivich","year":"2006","unstructured":"Daskivich TJ, Regan MM, Oh WK (2006) Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 176: 1927\u20131937","journal-title":"J Urol"},{"key":"BF6605322_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0959-8049(97)89027-2","volume":"33","author":"R de Wit","year":"1997","unstructured":"de Wit R, Pawinsky A, Stoter G, van Oosterom AT, Foss\u00e5 SD, Paridaens R, Svedberg A, de Mulder PH (1997) EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. Eur J Cancer 33: 493\u2013495","journal-title":"Eur J Cancer"},{"key":"BF6605322_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc801","volume":"2","author":"S Denmeade","year":"2002","unstructured":"Denmeade S, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev Cancer 2: 389\u2013396","journal-title":"Nat Rev Cancer"},{"key":"BF6605322_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1569-9056(06)61061-0","volume":"5","author":"B Escudier","year":"2006","unstructured":"Escudier B, Szczylik C, Eisen T, Oudard S, Stadler WM, Schwartz B, Shan M, Bukowski RM (2006) Randomized phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur Urol Suppl 5: 287","journal-title":"Eur Urol Suppl"},{"key":"BF6605322_CR13","first-page":"1888","volume":"7","author":"WD Figg","year":"2001","unstructured":"Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kr\u00fcger EA, Gubish E, Pluda JM, Reed E (2001) A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7: 1888\u20131893","journal-title":"Clin Cancer Res"},{"key":"BF6605322_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1015626410273","volume":"20","author":"WD Figg","year":"2002","unstructured":"Figg WD, Kruger EA, Price DK, Kim S, Dahut WD (2002) Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 20: 183\u2013194","journal-title":"Invest New Drugs"},{"key":"BF6605322_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00000658-197203000-00014","volume":"175","author":"J Folkman","year":"1972","unstructured":"Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409\u2013416","journal-title":"Ann Surg"},{"key":"BF6605322_CR16","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1158\/1078-0432.CCR-04-1560","volume":"11","author":"DJ George","year":"2005","unstructured":"George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW (2005) The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 11: 1815\u20131820","journal-title":"Clin Cancer Res"},{"key":"BF6605322_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1570-9124(03)00008-4","volume":"1","author":"A Heidenreich","year":"2003","unstructured":"Heidenreich A, Schrader AJ (2003) The treatment of hormone refractory prostate cancer. EAU Update Series 1: 40\u201350","journal-title":"EAU Update Series"},{"key":"BF6605322_CR18","first-page":"293","volume":"1","author":"CB Huggins","year":"1941","unstructured":"Huggins CB, Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293\u2013297","journal-title":"Cancer Res"},{"key":"BF6605322_CR19","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/pros.20509","volume":"66","author":"JT Isaacs","year":"2006","unstructured":"Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Bj\u00f6rk A, Olsson A, Leanderson T (2006) Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 66: 1768\u20131778","journal-title":"Prostate"},{"key":"BF6605322_CR20","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1021\/jm031044w","volume":"47","author":"S J\u00f6nsson","year":"2004","unstructured":"J\u00f6nsson S, Andersson G, Fex T, Fristedt T, Hedlund G, Jansson K, Abramo L, Fritzson I, Pekarski O, Runstr\u00f6m A, Sandin H, Thuvesson I, Bj\u00f6rk A (2004) Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 47: 2075\u20132088","journal-title":"J Med Chem"},{"key":"BF6605322_CR21","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271\u20137278","journal-title":"Clin Cancer Res"},{"key":"BF6605322_CR22","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1212\/WNL.54.9.1726","volume":"54","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 54: 1726\u20131733","journal-title":"Neurology"},{"key":"BF6605322_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0959-8049(97)89028-4","volume":"33","author":"A Pawinski","year":"1997","unstructured":"Pawinski A, van Oosterom AT, de Wit R, Foss\u00e5 S, Croles J, Svedberg A, Lentz MA, de Mulder PH (1997) An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. Eur J Cancer 33: 496\u2013499","journal-title":"Eur J Cancer"},{"key":"BF6605322_CR24","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513\u20131520","journal-title":"N Engl J Med"},{"key":"BF6605322_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1525-1411.2001.32007.x","volume":"3","author":"DM Reese","year":"2001","unstructured":"Reese DM, Fratesi P, Corry M, Novotny W, Holmgren E, Small EJ (2001) A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 3: 65\u201370","journal-title":"Prostate J"},{"key":"BF6605322_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","volume":"12","author":"EP Rock","year":"2007","unstructured":"Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R (2007) Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12: 107\u2013113","journal-title":"Oncologist"},{"key":"BF6605322_CR27","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148\u20131159","journal-title":"J Clin Oncol"},{"key":"BF6605322_CR28","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","volume":"20","author":"O Smaletz","year":"2002","unstructured":"Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20: 3972\u20133982","journal-title":"J Clin Oncol"},{"key":"BF6605322_CR29","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1038\/sj.bjc.6604064","volume":"97","author":"S Steinbild","year":"2007","unstructured":"Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg D, Hochhaus A, Hanauske AR, Edler L, Burkholder I, Scheulen M (2007) A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 97: 1480\u20131485","journal-title":"Br J Cancer"},{"key":"BF6605322_CR30","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th\u00e9odore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502\u20131512","journal-title":"N Engl J Med"},{"key":"BF6605322_CR31","first-page":"401","volume":"143","author":"N Weidner","year":"1993","unstructured":"Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401\u2013409","journal-title":"Am J Pathol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605322","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:42:02Z","timestamp":1684413722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,15]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["BF6605322"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605322","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,15]]}}}